

International Network of Safe Medication Practice Centres

Joining together worldwide to save lives

Sharing data from the Pharmacovigilence system in the UK

Weekly sharing of vigilance reports with medication error / human factors issues

MHRA			ANONYM	SED SINGLE	PATIENT REPO	DRT			GB-M	HRA-ADR 202	80626
Worldwide Reference MHRA ADR Number MHRA Version Numb		GB-MHRA-ADR 20280526 ADR 20280526-001 1	Y .Yes		Literature Refe	erence					
Company Reference Patient Details	No	GB-HAMELN-20080623-04									
Inifiais PRIVACY	Patient Sex FEMALE	Patient Age Pa 41YEARS	tient Age Group	Patient V	Veight (kg) Pa	atient Last Mens	strual Date	Gestation Period	at Time of Rea	action	
Report Seriousness											_
Reporter Considered Y	Serious Conge N	nital Abnormality Disabilit	y / Incapacity Hi N	ospitalised Du	e to Reaction	Life Threate N	-	Patient Died N	Other Media Y	oaily Significa	int
Parent/ Child (P/C) R	eaction: Parent D)etallis									
Parent 8ex		Parent Age	Parent Weight ((kg) Parent L	.ast Menstrual	Date					
Drug/ Product Detail Product Name	6	Drug Ch	araoterication	Aotive Const	tuent (8)						
MIDAZOLAM		SUSPEC		MIDAZOLAM							
Drug Name		Drug Charaoterisation	Batoh Number	Indicatio	n Name			Route of Admini	stration D	068	Docages/interval
MIDAZOLAM		SUSPECT		DRUG A	DMINISTRATIC	N ERROR		INTRAVENOUS	10	Dmg	
Drug Name		Drug Charaoterication	Strength Dr	ug Start Date	Drug End Date	Duration	Rechalleng		ten With Drug	Gestation P	eriod at Time of Exposure
MIDAZOLAM		SUSPECT					UNKNOWN	UNKNOW	N		
Reported Reaction D											
Reaction (LLT) Meddra Version	PT Term	Reaction Outcome	Reaction Start Date	t Reaction En Date	d Oncet Time (Start of Drug			Severity of Reaction	Reaction Treated?	Treatment Description
LOSS OF CONSCIOUSNES	SS 11.0	LOSS OF CONSCIOUSNESS	RECOVERED/ RESOLVED	02/10/2007					UNKNOWN	Unknown	
WRONG DRUG ADMINISTERE		WRONG DRUG ADMINISTERED	UNKNOWN						UNKNOWN	Unknown	
Fatal Report							_				
Patient Death Date	Post Mort	em Performed Flag	COD Unknown	Flag Su	idden Death Fl	ag					
							Re	ported Cause(s) of D	eath		
Patient History											
Patient Med History	Term(s)	Patient Med His	Continuing Flag	Patient Episo	ode Start Date	Patient Episod	e End Date	Patient Med Hist Co	atnemm		

ANONYMISED SINGLE PATIENT REPORT

GB-MHRA-ADR 20280526

Patient Drug History

MHRA

Patient Historic Drug Name	Patient Hist Indication Term(s)	Drug Start Date	Drug End Date	Patient Hist Reaction Term(s)

Parent History

Parent Drug History

Parent Historic Drug Name	Parent Hist Indication Term(s)	Parent Past Drug Start Date	Parent Past Drug End Date	Parent Hist Reaction Term(s)

Test Results

Test Performed Date	Test Name	Test Result	Low Test Range	High Test Range	Report On File Flag

Additional Test	

Reaction Text:

A female nauseous patient was prescribed intravenous metoclopramide 10 mg for nausea. A staff nurse accidentally administered 10 mg of midazolam intravenously and the patient collpased. The nurse became immediately aware of her error and corrective treatment was initiated. The patient made full recovery on the same afternoon.

Reporter Comments:

The reporter considers the existence of three contributing factors: the drugs were allocated in a drug cupboard next to each other, both drugs have similar coloured boxes and begin with M. Contradictorily, the event was assessed as not possibly related to the suspect drug by the reporter.

HRA ADR Number ADR 20205619-000 Y - Yes 3 MERA Version Number 3 U - Unknown String Version Number 3 U - Unknown Company Reference Patient Ass Patient Ass Patient Ass PRIVACY FEMALE 22YEARS Patient Ass Manual Addition Patient Ass PRIVACY FEMALE 22YEARS Patient Ass Manual Addition Patient Ass PRIVACY FEMALE 22YEARS Patient Ass Manual Addition Strong Company Reference Patient Ass Manual Addition Manual Addition Strong Company Reference Patient Addition N N Y Strong Company Reference Patient Addition N Y Y Pat	MHRA			ANONYMI	ISED SINGLE PATIENT REF	ORT			GB-GlaxoSmithKline	-B036077
AIREA ADR Number ADR 20005 0000 1 - 10 Max VHRA Version Number 0	Worldwide Reference Number	GB-GlaxoSmithKline-i	80360774A	Flag Key	Literature Re	ference				
	MHRA ADR Number			V VAL						
Patient Barie PRIVACY FEMALE 22YEAR PRIVACY FEMALE 22YEAR Report Serious Consential Abnormatify Disability I inequencity Nospitalized Due to Researce Report Serious Consential Abnormatify Disability I inequencity Nospitalized Due to Researce Report Serious Consential Abnormatify Disability I inequencity Nospitalized Due to Researce Report Serious Consential Abnormatify Disability I inequencity Nospitalized Due to Researce Report Serious Consential Abnormatify Disability I magnetity Nospitalized Due to Researce Report Considered Serious Consential Abnormatify Disability I magnetity Nospitalized Due to Researce Report Considered Serious Consential Abnormatify Disability I magnetity Nospitalized Due to Researce Report Considered Serious Consential Abnormatify Disability I magnetity Nospitalized Due to Researce Report Consection: Parent Details Parent Sex Parent Age Parent Details Parent Sex Parent Age Dirug Characterization Advine Constituent (3) Parent Sex Constituent Conste	MHRA Version Number									
PRIVACY FEMALE 22YEAR8 Report Seriousneed Report Seri	Company Reference No Patient Details	GB-GlaxoSmithKline-	B0360774A							
Report Serious Companies Descentes Report Serious Considered Serious Congenital Abnormatity Disability / Insapabity Nesset Considered Serious Patient Disability / Insapabity N N N Y Parent Good Serious Considered Serious N N N N Y Parent Good (PitO) Readition: Farent Details Parent Wold(N2) Parent Last Mendmail Date Y Dang/ Produal Details Parent Mage Parent Wold(N2) Parent Last Mendmail Date Y Dang/ Produal Details Parent Mage Parent Wold(N2) Parent Mage Y Parent Manue Dang/ Produal Details Parent Mage Parent Wold(N2) Parent Mage Y Parent Manue Dang/ Produal Details Parent Mage Parent Wold(N2) Parent Mage Parent Wold(N2) Parent Mage Parent Mage Parent Manue Durg Charawarderitable Adive Constituent (S) Parent Mage Parent Parent Mage Parent Mage Parent Pa			Pat	ient Age Group	Patient Weight (kg)	Patient Last Menstri	ual Date G	estation Period at	Time of Reaction	
Reporter Considered Serious: Congenital Abnormality Disability / Incapabily Hospitalized Due to Reackion Life Threatening Patient Died Other Medically Significant r N N N N N N Y Parent Unitid (PIC) Reaction: Farent Defails Parent Medically Significant Parent Medically Significant Y Parent Sas Parent Applicant Advec Constituent (S) Y Y Onlog Produot Defails Parent Medically Significant Advec Constituent (S) Y Produot Manne Durg Charaderication Advec Constituent (S) Y ARXOVETINE HYDROCHLORIDE DUSPECT Parent Acti MenoStruet (S) Y NUTRIPTYLINE OTHER Advec Constituent (S) Y NUTRIPTYLINE OTHER OITALOPRAM Y Y DIAZEPAM OTHER OITALOPRAM Y Y DULOXETINE OTHER DULOXETINE Y SEXUME OTHER FLUOXETINE Y DULOXETINE OTHER FLUOXETINE Y	PRIVACY FEMAL	E 22YEAR	8							
Reporter Considered Serious: Congenital Abnormality Disability / Incapabily Hospitalized Due to Reackion Life Threatening Patient Died Other Medically Significant r N N N N N N Y Parent Unitid (PIC) Reaction: Farent Defails Parent Medically Significant Parent Medically Significant Y Parent Sas Parent Applicant Advec Constituent (S) Y Y Onlog Produot Defails Parent Medically Significant Advec Constituent (S) Y Produot Manne Durg Charaderication Advec Constituent (S) Y ARXOVETINE HYDROCHLORIDE DUSPECT Parent Acti MenoStruet (S) Y NUTRIPTYLINE OTHER Advec Constituent (S) Y NUTRIPTYLINE OTHER OITALOPRAM Y Y DIAZEPAM OTHER OITALOPRAM Y Y DULOXETINE OTHER DULOXETINE Y SEXUME OTHER FLUOXETINE Y DULOXETINE OTHER FLUOXETINE Y	Report Seriousness									
Parenti Child (PIC) Reaction: Parent Details Parent Sex		ngenital Abnormality	Disability	/ Incapacity Ho	ospitalised Due to Reaction	Life Threatenin	ng Patie	nt Died	Other Medically Signif	loant
Parent Age Parent Weight (bg) Parent Last Mendrual Date Drug / Product Name Drug Charasoleritation Adive Conditiant (3) ARACKETINE HYDROCHLORIDE DUSPECT PAROXETINE RISPERIDONE DUSPECT RISPERIDONE MITRIPTYLINE OTHER AMITRIPTYLINE DITALOPRAM OTHER OTHER DIVORDODEINE OTHER DIVORDODEINE DOBULEPINE OTHER DUVERTINE DULOXETINE OTHER DUVERDODEINE DULOXETINE OTHER DUVERDODEINE DULOXETINE OTHER DULOXETINE DULOXETINE OTHER DULOXETINE DULOXETINE OTHER DULOXETINE DULOXETINE OTHER DULOXETINE DULOXETINE OTHER VENLAFAXINE HYDROCHLORIDE FLUOXETINE OTHER VENLAFAXINE HYDROCHLORIDE DULOXETINE OTHER LORMETAZEPAM OTHER LORMETAZEPAM OTHER OTHER LORMETAZEPAM OTHER ORAZEPAM OTHER	Y N		N	N		N	N		Y	
Parent Age Parent Weight (bg) Parent Last Mendrual Date Drug / Product Name Drug Charasoleritation Adive Conditiant (3) ARACKETINE HYDROCHLORIDE DUSPECT PAROXETINE RISPERIDONE DUSPECT RISPERIDONE MITRIPTYLINE OTHER AMITRIPTYLINE DITALOPRAM OTHER OTHER DIVORDODEINE OTHER DIVORDODEINE DOBULEPINE OTHER DUVERTINE DULOXETINE OTHER DUVERDODEINE DULOXETINE OTHER DUVERDODEINE DULOXETINE OTHER DULOXETINE DULOXETINE OTHER DULOXETINE DULOXETINE OTHER DULOXETINE DULOXETINE OTHER DULOXETINE DULOXETINE OTHER VENLAFAXINE HYDROCHLORIDE FLUOXETINE OTHER VENLAFAXINE HYDROCHLORIDE DULOXETINE OTHER LORMETAZEPAM OTHER LORMETAZEPAM OTHER OTHER LORMETAZEPAM OTHER ORAZEPAM OTHER	Parenti Child (P/C) Readion: Pare	of Details								
Product NameDrug CharaolanisationAddive Constituent (8)PAROXETINE HYDROCHLORIDEDUBPECTPAROXETINERIBPERIDONEDUBPECTRIBPERIDONEMITRIPTYLINEOTHERAMITRIPTYLINEDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDULOXETINEDOULOXETINEOTHERDULOXETINEDUAZETINEOTHERVENLAFAXINE HYDROCHLORIDEDUAXETINEOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERNETHADONELORAZEPAMOTHERNETHADONELORAZEPAMOTHERNETHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZENINEOTHERREHADONELORAZENINEOTHER<	Parent 8ex		0	Parent Weight ((kg) Parent Last Menstru	al Date				
Product NameDrug CharaolanisationAddive Constituent (8)PAROXETINE HYDROCHLORIDEDUBPECTPAROXETINERIBPERIDONEDUBPECTRIBPERIDONEMITRIPTYLINEOTHERAMITRIPTYLINEDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDULOXETINEDOULOXETINEOTHERDULOXETINEDUAZETINEOTHERVENLAFAXINE HYDROCHLORIDEDUAXETINEOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERNETHADONELORAZEPAMOTHERNETHADONELORAZEPAMOTHERNETHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZENINEOTHERREHADONELORAZENINEOTHER<										
Product NameDrug CharaolanisationAddive Constituent (8)PAROXETINE HYDROCHLORIDEDUBPECTPAROXETINERIBPERIDONEDUBPECTRIBPERIDONEMITRIPTYLINEOTHERAMITRIPTYLINEDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDIAZEPAMDIAZEPAMOTHERDULOXETINEDOULOXETINEOTHERDULOXETINEDUAZETINEOTHERVENLAFAXINE HYDROCHLORIDEDUAXETINEOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERNETHADONELORAZEPAMOTHERNETHADONELORAZEPAMOTHERNETHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZEPAMOTHERREHADONELORAZENINEOTHERREHADONELORAZENINEOTHER<	Drugi Broduct Datalla	·		•						
PAROXETINE HYDROCHLORIDEDUBPECTPAROXETINERIBPERIDONEBUBPECTRIBPERIDONERIBPERIDONEOTHERAMITRIPTYLINEDITALORAMOTHEROTALORAMDIAZEPAMOTHERDIAZEPAMDOULDENIEOTHERDIAZEPAMDOULDENIEOTHERDIAZEPAMDOULDENIEOTHERDIAZEPAMDOULDENIEOTHERDIAZEPAMDOULDENIEOTHERDIAZEPAMDOULDENIEOTHERDIAZEPAMDOULDENIEOTHERDUINTRECODENIEDOULDENIEOTHERDUINTREDOULDENIEOTHERDUINTREDOULDENIEOTHERDUINTREDOULDENIEOTHERDUINTREDOULDENIEOTHERDUINTREDOULDENIEOTHERLORAZEPAMDORAZEPAMOTHERLORAZEPAMOTHEROTHERLORAZEPAMOTHEROTHERMITAZAPINENIRTAZAPINEOTHEROTHERRIBTAZENAOTHEROTHERALINE HYDROCHLORIDERIBTAZENAOTHEROTHERALINERIBTAZENIEOTHEROTHERALINERIBTAZENIEOTHEROTHERALINERIBTAZENIEOTHEROTHERALINERIBTAZENIEOTHEROTHERALINERIBTAZENIEOTHEROTHERALINERIBTAZENIEOTHEROTHERALINERIBTAZENIEOTHEROTHERALINERIBTAZENIEOTHEROTHERALINERIBTAZENIEOTHEROTHERALINERIBTATIONEOTHEROTHERALIN	Product Name		Drug Cha	aracterisation	Aotive Constituent (8)					
WITRIPTYLINEOTHERAMITRIPTYLINEDIAZEPAMOTHERCITALOPRAMDIAZEPAMOTHERDIAZEPAMDIAYDROCODEINEOTHERDIHYDROCODEINEDOBULEPINEOTHERDOTHIEPINDULOXETINEOTHERDULOXETINESTEXOROTHERVENLAFAXINE HYDROCHLORIDEFLUOXETINEOTHERLOFEPRAMINE HYDROCHLORIDECLOXETINEOTHERLOFEPRAMINE HYDROCHLORIDESAMANILOTHERLOFEPRAMINE HYDROCHLORIDELORAZEPAMOTHERLORAZEPAMJORMETAZEPAMOTHERLORMETAZEPAMMIRTAZAPINEOTHERMIRTAZAPINEDIRLIGTATOTHERORLIGTATPROTHIADENOTHERDOTHERINEDIRLIGTATOTHERMIRTAZAPINEDIRLIGTATOTHERQUETIAPINEREBOXETINEOTHERREBOXETINEROACCUTANEOTHERREBOXETINEROACCUTANEOTHERREBOXETINE	PAROXETINE HYDROCHLORIDE				PAROXETINE					
DitaLOPRAMOTHERDitALOPRAMDIAZEFAMOTHERDIAZEFAMDIAZEFAMOTHERDIAZEFAMDIHYDROCODEINEOTHERDIHYDROCODEINEDOBULEPINEOTHERDOTHIEPINDULOXETINEOTHERDULOXETINESERXOROTHERVENLAFAXINE HYDROCHLORIDEFLUOXETINEOTHERFLUOXETINESAMANILOTHERLOFEPRAMINE HYDROCHLORIDELORAZEPAMOTHERLORAZEPAMLORMETAZEPAMOTHERLORMETAZEPAMMIETHADONEOTHERMIRTAZAPINEDRLIBTATOTHEROTHERPROTHIADENOTHERDOTHIEPIN HYDROCHLORIDEDILIBTATOTHERMIRTAZAPINEDOTHEROTHEROTHERREBOXETINEOTHERQUETIAPINEREBOXETINEOTHERBOTHERINEREBOXETINEOTHERBOTHERINEREBOXETINEOTHERBOTHERINEROACCUTANEOTHERBOTRETINDIN	RISPERIDONE		SUSPEC.	T	RISPERIDONE			1		
DIAZEPAMOTHERDIAZEPAMDIHYDROCODEINEOTHERDIHYDROCODEINEDOGULEPINEOTHERDOTHIEPINDULOXETINEOTHERDULOXETINESERXOROTHERVENLAFAXINE HYDROCHLORIDEFLUOXETINEOTHERLOFEPRAMINE HYDROCHLORIDESAMANILOTHERLOFEPRAMINE HYDROCHLORIDELORAZEPAMOTHERLORAZEPAMLORMETAZEPAMOTHERLORAZEPAMMIETHADONEOTHERLORMETAZEPAMMIETAZAPINEOTHERMIRTAZAPINEDALIBTATOTHEROTHIEPIN HYDROCHLORIDEDALIBTATOTHEROTHIEPIN HYDROCHLORIDEDALIBTATOTHEROTHIEPIN HYDROCHLORIDEDALIBTATOTHERQUETIAPINEQUETIAPINEOTHERQUETIAPINEQUETIAPINEOTHERQUETIAPINEROBOXETINEOTHERREBOXETINEROBOXETINEOTHERBOTRETINOIN	AMITRIPTYLINE		OTHER		AMITRIPTYLINE			1		
DIHYDROCODEINEOTHERDIHYDROCODEINEDOBULEPINEOTHERDOTHIEPINDULOXETINEOTHERDULOXETINEEFEXOROTHERVENLAFAXINE HYDROCHLORIDEFLUOXETINEOTHERFLUOXETINEGAMANILOTHERLOFEPAMINE HYDROCHLORIDELORAZEPAMOTHERLORAZEPAMLORAZEPAMOTHERLORMETAZEPAMANTADONEOTHERLORMETAZEPAMMIRTAZAPINEOTHERMIRTAZAPINEDRILBTATOTHERORLIGTATPROTHIADENOTHERDOTHIEPIN HYDROCHLORIDEDIRLBTATOTHERDOTHIEPIN HYDROCHLORIDEDIRLBTATOTHERDOTHIEPIN HYDROCHLORIDEDIRLBTATOTHERDOTHIEPIN HYDROCHLORIDEDIRLBTATOTHERDOTHIEPIN HYDROCHLORIDEDIRLBTATOTHERREBOXETINEROACCUTANEOTHERREBOXETINEROACCUTANEOTHERIBOTRETINOIN	CITALOPRAM		OTHER		CITALOPRAM			1		
DOSULEPINEOTHERDOTHIEPINDULOXETINEOTHERDULOXETINEDULOXETINEOTHERVENLAFAXINE HYDROCHLORIDEFLUOXETINEOTHERFLUOXETINESAMANILOTHERLOFEPRAMINE HYDROCHLORIDELORAZEPAMOTHERLORAZEPAMLORMETAZEPAMOTHERLORMETAZEPAMMETHADONEOTHERLORMETAZEPAMMIRTAZAPINEOTHERRETADONEDALIBTATOTHERORLISTATPROTHIADENOTHEROTHERINH HYDROCHLORIDEZUETIAPINEOTHEROTHERINH MIRTAZAPINEROMUHADENOTHERQUETIAPINEROMUHADENOTHERQUETIAPINEROBOXETINEOTHERQUETIAPINEROBOXETINEOTHERREBOXETINEROACOUTANEOTHERISOTRETINDIN	DIAZEPAM		OTHER		DIAZEPAM			1		
DULOXETINEOTHERDULOXETINEDULOXETINEOTHERVENLAFAXINE HYDROCHLORIDEEFEXOROTHERVENLAFAXINE HYDROCHLORIDEGAMANILOTHERLOFEPRAMINE HYDROCHLORIDELORAZEPAMOTHERLORAZEPAMLORMETAZEPAMOTHERLORMETAZEPAMMETHADONEOTHERMETHADONEMIRTAZAPINEOTHERMETHADONEDRIJBTATOTHERORLIBTATPROTHIADENOTHERDOTHIEPIN HYDROCHLORIDEQUETIAPINEOTHERQUETIAPINEREBOXETINEOTHERREBOXETINEROACOUTANEOTHERIGOTRETINOIN	DIHYDROCODEINE		OTHER		DIHYDROCODEINE			1		
EFEXOROTHERVENLAFAXINE HYDROCHLORIDEFLUOXETINEOTHERFLUOXETINEBAMANILOTHERLOFEPRAMINE HYDROCHLORIDELORAZEPAMOTHERLORAZEPAMLORMETAZEPAMOTHERLORMETAZEPAMLORMETAZEPAMOTHERLORMETAZEPAMMIETHADONEOTHERMIETHADONEMIETAZAPINEOTHERMIETAZAPINEDRLIBTATOTHEROTHIEPIN HYDROCHLORIDEPROTHIADENOTHERDOTHIEPIN HYDROCHLORIDEQUETIAPINEOTHERQUETIAPINEREBOXETINEOTHERREBOXETINEROACCUTANEOTHERIBOTRETINDIN	DOSULEPINE		OTHER		DOTHIEPIN			1		
FLUOXETINEOTHERFLUOXETINEGAMANILOTHERLOFEPRAMINE HYDROCHLORIDELORAZEPAMOTHERLORAZEPAMLORMETAZEPAMOTHERLORMETAZEPAMLORMETAZEPAMOTHERLORMETAZEPAMMETHADONEOTHERMETHADONEMIRTAZAPINEOTHERMIRTAZAPINEDRLIBTATOTHEROTHERINPROTHIADENOTHERDOTHIEPIN HYDROCHLORIDEQUETIAPINEOTHERQUETIAPINEQUETIAPINEOTHERREBOXETINEREBOXETINEOTHERREBOXETINEROACCUTANEOTHERBOTRETINOIN	DULOXETINE		OTHER		DULOXETINE			1		
BAMANILOTHERLOFEPRAMINE HYDROCHLORIDEJORAZEPAMOTHERLORAZEPAMLORMETAZEPAMOTHERLORMETAZEPAMMETHADONEOTHERMETHADONEMIRTAZAPINEOTHERMIRTAZAPINEDRLIBTATOTHERORLIBTATPROTHIADENOTHERDOTHIEPIN HYDROCHLORIDEQUETIAPINEOTHERQUETIAPINEREBOXETINEOTHERREBOXETINEROACCUTANEOTHERIBORRETINDIN	EFEXOR		OTHER		VENLAFAXINE HYDROCH	LORIDE		1		
LORAZEPAMOTHERLORAZEPAMJORMETAZEPAMOTHERLORMETAZEPAMMETHADONEOTHERMETHADONEMIRTAZAPINEOTHERMIRTAZAPINEORLISTATOTHERORLISTATPROTHIADENOTHERDOTHIEPIN HYDROCHLORIDEQUETIAPINEOTHERQUETIAPINEREBOXETINEOTHERREBOXETINEROACCUTANEOTHERIBOTRETINDIN	FLUOXETINE		OTHER		FLUOXETINE					
LORMETAZEPAMOTHERLORMETAZEPAMMETHADONEOTHERMETHADONEMIRTAZAPINEOTHERMIRTAZAPINEDRLISTATOTHERORLISTATPROTHIADENOTHERDOTHIEPIN HYDROCHLORIDEQUETIAPINEOTHERQUETIAPINEREBOXETINEOTHERREBOXETINEROACCUTANEOTHERISOTRETINOIN	GAMANIL		OTHER		LOFEPRAMINE HYDROCH	LORIDE		1		
METHADONEOTHERMETHADONEMIRTAZAPINEOTHERMIRTAZAPINEDRLISTATOTHERORLISTATPROTHIADENOTHERDOTHIEPIN HYDROCHLORIDEQUETIAPINEOTHERQUETIAPINEREBOXETINEOTHERREBOXETINEROACCUTANEOTHERISOTRETINDIN	LORAZEPAM		OTHER		LORAZEPAM			1		
MIRTAZAPINE OTHER MIRTAZAPINE DRLISTAT OTHER ORLISTAT PROTHIADEN OTHER DOTHIEPIN HYDROCHLORIDE QUETIAPINE OTHER QUETIAPINE REBOXETINE OTHER REBOXETINE ROACCUTANE OTHER IBOTRETINDIN	LORMETAZEPAM		OTHER		LORMETAZEPAM					
DRLISTAT OTHER ORLISTAT PROTHIADEN OTHER DOTHIEPIN HYDROCHLORIDE QUETIAPINE OTHER QUETIAPINE REBOXETINE OTHER REBOXETINE ROACCUTANE OTHER ISOTRETINOIN	METHADONE		OTHER		METHADONE					
PROTHIADEN OTHER DOTHIEPIN HYDROCHLORIDE QUETIAPINE OTHER QUETIAPINE REBOXETINE OTHER REBOXETINE ROACCUTANE OTHER IBOTRETINDIN	MIRTAZAPINE		OTHER		MIRTAZAPINE					
QUETIAPINE OTHER QUETIAPINE REBOXETINE OTHER REBOXETINE ROACCUTANE OTHER IBOTRETINDIN	ORLISTAT		OTHER		ORLISTAT					
REBOXETINE OTHER REBOXETINE ROACCUTANE OTHER ISOTRETINDIN	PROTHIADEN		OTHER		DOTHIEPIN HYDROCHLO	RIDE				
ROACCUTANE OTHER ISOTRETINOIN	QUETIAPINE		OTHER		QUETIAPINE					
	REBOXETINE		OTHER		REBOXETINE					
RAZODONE OTHER TRAZODONE	ROACCUTANE		OTHER		ISOTRETINOIN					
	TRAZODONE		OTHER		TRAZODONE			1		

MHRA	
Drug Name	Drug Characterisation
PAROXETINE HYDROCHLORIDE	SUSPECT
RISPERIDONE	SUSPECT
AMITRIPTYLINE	OTHER
CITALOPRAM	OTHER
DIAZEPAM	OTHER
DIHYDROCODEINE	OTHER
DOBULEPINE	OTHER
DULOXETINE	OTHER
EFEXOR	OTHER
FLUOXETINE	OTHER
GAMANIL	OTHER
LORAZEPAM	OTHER
LORMETAZEPAM	OTHER
METHADONE	OTHER
MIRTAZAPINE	OTHER
ORLISTAT	OTHER
PROTHIADEN	OTHER
QUETIAPINE	OTHER
REBOXETINE	OTHER
ROACCUTANE	OTHER
TRAZODONE	OTHER

ANONYMISED & NOLE PATIENT F

MHRA

Reported Reaction Details

Reaction (LLT)	Meddra	PT Term	Reaction	Reaction Start Reaction
AGGRESSION	Version 11.0	AGGRESSION	Outcome UNKNO/WN	Date Dat 13/08/1999
AGITATION	11.0	AGITATION	UNKNOWN	13/08/1999
BALANCE DIFFICULTY	11.0	BALANCE DISORDER	UNKNOWN	08/1999
BLURRED VISION	11.0	VISION BLURRED	UNKNOWN	13/08/1999
CONFUSION	11.0	CONFUSIONAL STATE	UNKNOWN	13/08/1999
DELIBERATE SELF-HARM	11.0	INTENTIONAL SELF-INJURY	UNKNOWN	12/10/2006
DIARRHEA	11.0	DIARRHOEA	UNKNOWN	13/08/1999
DIZZINESS	11.0	DIZZINESS	UNKNOWN	03/1999
ELECTRIC SHOCK SENSATION	11.0	PARAESTHESIA	UNKNOWN	13/08/1999
FATIGUE	11.0	FATIGUE	UNKNOWN	13/08/1999
FLU SYMPTOMS	11.0	INFLUENZA	UNKNOWN	13/08/1999
HAIR DISORDER	11.0	HAIR DISORDER	UNKNOWN	07/1999
HEAD INJURY	11.0	HEAD INJURY	UNKNOWN	06/1999
JERKINESS	11.D	DYSKINESIA	UNKNOWN	13/08/1999
LETHARGY	11.0	LETHARGY	UNKNOWN	13/08/1999
LOW MOOD	11.0	DEPRESSED MOOD	UNKNOWN	13/08/1999
MEMORY DEFICIT	11.0	MEMORY IMPAIRMENT	UNKNOWN	13/08/1999
OVERDOSE	11.0	OVERDOSE	UNKNOWN	12/10/2006
OVERDOSE	11.0	OVERDOSE	UNKNOWN	20/06/2006
PANIC ATTACK	11.0	PANIC ATTACK	UNKNOWN	08/1999
SCALP INJURY NOS	11.0	SKIN INJURY	UNKNOWN	06/1999
SLEEP DISTURBANCE	11.0	SLEEP DISORDER	UNKNOWN	13/08/1999
SLEEPINESS	11.0	SOMNOLENCE	UNKNOWN	06/2002
SUICIDAL BEHAVIOR	11.0	SUICIDAL BEHAVIOUR	UNKNOWN	13/08/1999
SUICIDAL IDEATION	11.0	SUICIDAL IDEATION	UNKNOWN	13/08/1999
SWEATING	11.0	HYPERHIDROSIS	UNKNOWN	13/08/1999
VERTIGO	11.0	VERTIGO	UNKNOWN	13/08/1999
VIOLENCE	11.0	AGGRESSION	UNKNOWN	13/08/1999
VOMITING	11.0	VOMITING	UNKNOWN	13/08/1999
WITHDRAWAL REACTION	11.0	WITHDRAWAL SYNDROME	UNKNOWN	13/08/1999

Patient History

Patient Med History Term(s)

ACINE

ALCOHOL ABUSE

DEPRESSION

DRUG ABUSE

DRUG ABUSE

ECZEMA

OVERDOSE

OVERDOSE

OVERDOSE

SELF ESTEEM DECREASED

STRESS

Patient Drug History

MHRA

Reaction Text:

This case was reported by a lawyer (in relation to alleged 'withdrawai') and described the occurrence of withdrawai in a female patient who received paroxetine. This narrative has been written after review of medical notes provided as part of the action received on 15th August 2005(This patient has a history of acre and eczema managed by a dermatologist, "She has a history of depression relating to previous skin problems". After trying amitriplyline and Edronax which were not tolerated, the patient was switched to parovetine 20mp daily on 29/04/1998. Out of hours service notes 26-03-1999: stopped parovetine 'Monday' and 'feels dizzy etc'. Out of hours service notes 13-08-1999; weaning off parovetine but experiencing problems with panic attacks and loss of balance. 'Happened before when came off'. (NOS)There appears to have been an interaction between the patient and a solicitor reparding a claim for damages arising out of damage to her hair which occurred in July 1999' which seems to have occurred when the patient was wearing herself off paroxetine. "3he suffered considerable damage to her scale and head in June 1999 and this caused her further depression" (solicitor's letter to GP). (The GP responded that the patient was treated for dandruff.) Another letter from the GP to the solicitor states that the patient had contacted the surgery on 21/06/1999 and 14/08/1999 to say that she couldn't cope without her paroxetine and low doses (unclear) were continued. On 28/06/2002 the patient had low mood, her dose of paraxetine was increased to 40mp daily and she requested amphetamines -declined. The patient appears to have been switched to veniataxine in April 2003 as she was feeling very low and too sleepy on paroxetine. She was seen. In A&E following overdose of 20 x 75mg veniafaxine on 21-08-2004 but took her own discharge against medical advice. In March 2005, she had an urgent referral for suicidal ideation without intent (having come off veniatavine 5 months earlier: A letter from psychiatrist dated 20/04/2005 savs that the patient now felt that her depression had started after the birth of her child 8 years earlier: had been on several antidepressants which worked for a while: 'feit that paroxetine 'did something funny to her' and she has since become amotivated and lethargic'. The psychiatrist did not feel that the patient needed input from the mental health team. The patient took an overdose and attended A&E on 25/07/2005 but did not wait to be seen by doctor. (Her druos were not specified but the other notes suggest that she would have been taking beforemine at the time.) Follow up information received on 05 May 2005/No additional relevant information was identified in this set of hospital notes. This case was received as part of a legal action- medical records available on request. Follow-up received on 03 January 2008.A Claimant Schedule of Information, completed and sloned by the claimant, was received by GSK from the claimant's lawyers. Pre-prescription medical conditions were listed as decreasion. The claimant stated that there were not any pre-existing conditions of a nature relevant or similar to the alleged injuries. Beroxat was first prescribed on 29 April 1998 and was subsequently prescribed at various dates between 16 September 1998 and 04 October 2005. Other anti-depressant medication taken during this period by the patient included veniataxine hydrochloride, iormetazepam, iorazepam, ior injuries included apliation, confusion, diarrhoea, electric zaos, jotino, appression, sweatino, vertioo, 'server' sleep disturbance, flu symptoms, fatioue, suicidal, blurred vision, dizziness, vomitino, letharov, oppr memory and violent outburst. The date of first onset (not further specified) was 13 August 1999 and date of first diagnosis (not further specified) was 13 August 1999. The duration of the alleged injuries was 6 years. Additional information from medical records received 23 May 2008. The patient had a family history of mental liness with her mother, an aunt and two of her brothers being treated for depression and another aunt and a cousin having committed suicide by taking overdoses. The patient had variously claimed to have been depressed since a teenager or since the birth of her only child in November 1996. She had always noted a strong association with her menstrual cycles, being at her worst mood-wise for a week before mensitivation. The patient was treated twice with reaccutane in 1997 and 1998. This caused pruntis and a worsening of her eczema. The patient received at least two antidepressants (antitriptyline in October 1997 and fluoxetine in January 1998) prior to paroxetine. Paroxetine was prescribed from 29 April 1998 to 29 January 2003 when it was noted that she was "very low and too sleepy with fleeting thoughts of self harm'. She was changed to vehiafaxine and progranoiol and subsequently has had a significant number of antidepressants (including dosuleoine April 2005, guetapine July 2005, duloxetine May 2005. reboxetine July 2006 which caused sweating, citalogram December 2006 which caused vomiting, trazodone December 2006, mitazapine February 2007, risperidone May 2007 which seemed to produce worsening of suicidal Ideation when discontinued suddenly, fluoxetine again in November 2007). She was prescribed onlistst for weight loss in 2004. She has been described as a long standing depressive with underlying poor self esteem and poor self worth with poor coping strategies. Her care had been compromised by her frequent non-attendance at appointments, referrals and therapeutic interventions. She had taken a number of overdoses at times of stress (August 2004. Sectember 2004. July 2005. November 2005. June 2006. October 2006 and July 2007). Her care has been further complicated by substance abuse (cannabis at school leading to paranola, amphetamines for weight loss before 2004, ecstasy, cocaine, dihydrocodeline in 2005, diazepam in 2005 and methadone in 2005). She has also abused alcohol with excessive consumption noted in 2006 (2x diazepam detoxifications required and 2 occasions of injury whilst intoxicated) and in 2007 it was noted she had a weekly intake of about 100 units. A letter dated 9 October 2007 reported "suicidal thoughts on and off for 2 years, last around a week then go away... worse... with... mensitual cycle approximately one week before period. Hearing one voice which she recognises as her own. Denies illicit drug use since Feb 2007 diagnosis situational crisis and mild depressive mood. 'On 6 May 2008 she was reported to be taking ambitiothine 10mg 1-2 at night with fluoxetine 40mg having been dispensed on 14 April 2008. She was complaining of abdominal pain in the right illac fossa and had a negative pregnancy test. She also admitted to a low mood and to hearing a voice (her own, inside her head). The outcome of the events is unknown. These medical records were received as part of a legal action and are available on request. The following information was obtained from medical records received 24 June 2008; On 20 June 2006, the patient ingested an overdose of 14 Valum tablets and 14 dosulepin tablets, with 2 cans of beer: there was also a "possibility of overdose of codyramol". She was treated in A&E where it was noted that she "expresses suicidal ideation". The patient was also agitated and aggressive and required sedation. The psychologist noted that she had taken the overdose "in response to on-going low mood and recent relationship breakdown", and "did deny any further active suicidal ideation". On 12 October 2005, the patient was treated in A&E following an alleged overdose of reboxetine and alcohol, recorded as "deliberate self-harm". She also had injuries to her face and stomach and a broken tooth, as a result of an "allcoed assault".

MHRA incident 14/7/08

- "Due to the patient's poor eyesight, a nurse administered the daily insulin glargine.
- On the day of the ADRs, the nurse who came to administer the insulin glargine had not seen the patient or the Opticlik before and had not received any training on the use of the Opticlik.
- When the nurse attempted dialling the Opticlik, the pen jammed. The next Opticlik pen she tried also jammed. The nurse then drew up the insulin glargine from within the Opticlik cartridge system with a needle and syringe.

- The nurse then drew up the insulin glargine from within the Opticlik cartridge system with a needle and syringe.
- The syringe was not an insulin syringe, and the nurse misread what she was supposed to administer.
- The patient was supposed to receive 36 units. The nurse injected three times, until the cartridge became empty, and then withdrew an additional 60 units from a second cartridge and injected this.
- The patient received a total of 360 units of insulin. Two to three hours later the patient was falling asleep in the car with a friend. The patient became hot, flushed, and did not feel well. She required assistance getting out of the car, and fell to the floor.
- The paramedics were called, and the patient died. It was reported that the patient had hypoglycaemia and her heart had stopped. The pens were independently tested due to this being a criminal case, and they were

Search of NPSA incident database

- Search date: 01Jan05 to 01Apr08
- Search Terms: 2 NRLS searches run
- 1/ "syringe" AND "insulin" AND "mls" (generated 102 incidents, of these 11 were found to be related)
- 2/ "not an insulin syringe" or "noninsulin syringe" or "non insulin syringe" (generated 1 incident)

NRLS Report

Degree of harm	Frequency	Validated
Death	0	0
Severe	0	0
Moderate	3	1
Low	3	6
No harm	6	5

Case report 1

- Comments by student midwife that midwife may have inadvertently given 0.8mls of insulin in a 1ml syringe with an orange needle.
- 8 iu were prescribed.
- Woman had severe hypo requiring dextrose and a sliding scale insulin. She reported her concerns to the midwife who came on duty on the next shift.
- Moderate

Case report 2

- Nurse was performing morning drug round preparing IM injections - one for injection of Insulatard (60 units - 1ml - 100units) and one heparin injection (5000units - 1ml - 5000units).
- Two syringes were on nurses' station, "an insulin syringe for Insulatard and a 10mls syringe for heparin.
- Nurse took three calls whilst standing "/ "preparing injections.
- Insulatard drawn up mistakenly in 10mls syringe

 amount drawn up 6 mls instead of 0.6mls. Staff
 nurse started to give, realised mistake after
 approx 3-4 mls given. Moderate

Case Report 3

- When setting up GKI infusion used wrong syringe
- added incorrect amount of insulin 1.2 mls instead of 12 units.

Case report 4

- Sliding scale insulin for patient.
- Drugs added label incorrect.
- Drug added actrapid, quantity 10mls.
- The correct dose for sliding scale is 50 units of actrapid not 10mls.

BBC NEWS

LIVE LE BBC NEWS CHANNEL

News Front Page World UK England Northern Ireland N Ireland Politics Scotland Wales Business Politics Health Education Science/Nature Technology Entertainment Also in the news Video and Audio Have Your Say Magazine In Pictures Country Profiles Special Reports SPORT WEATHER CBBC NEWSROUND

Last Updated: Monday, 3 September 2007, 13:08 GMT 14:08 UK

Printable version E-mail this to a friend Doctor gives fatal insulin dose

A 92-year-old man died of a heart attack after a junior doctor gave him a drugs overdose, an inquest has heard.

Walter Kenneth Johnston was injected with 100 times the correct dose of insulin by a junior doctor at Belfast City Hospital.



Mr Johnston was being treated at Belfast City Hospital

Dr Nuzaimin Ahmad claimed he did not know how to treat him.

He used the wrong syringe to administer the drug in the early hours of 25 February 2005. Dr Ahmad no longer practises in the UK.

Belfast Coroner's Court heard he had only been working at the hospital for three weeks.

RELATED BBC SITES ON THIS DAY EDITORS' BLOG

A letter from the doctor read out in court said he believed that "one unit of insulin was equivalent to one millilitre".

"I have not received any previous instruction in the handling of insulin," it said.

D Watch One-Minute World News

News se Your nev it

News Front Page Africa Americas Asia-Pacific Europe Middle East South Asia UK England Northern Ireland Scotland Wales UK Politics Education Magazine Business Health

Last Updated: Tuesday, 26 July, 2005, 16:24 GMT 17:24 UK

E-mail this to a friend Printable version Patient given 'insulin overdose'

Doctors in NI are to receive fresh guidance on how to administer insulin.

It follows an inquest into the death of an elderly woman who was given ten times the dose of insulin she needed.

The inquest heard Sarah Smith, 90, from Whiterock CHERRY HOSPITAL

The incident happened at Belfast City Hospital four years ago RELATED Departm Services The BBC i content o

TOP NOR Police at Joyriden Tourists

Parade in Belfast, became semi-conscious and died after
 choking on food. It happened four years ago.

ion The inquest was told it had emerged later that the junior ine doctor treating her at Belfast City Hospital had not been shown how to measure insulin.



News Front Page World UK England Northern Ireland N Ireland Politics Scotland Wales Business Politics Health Education Science/Nature Technology Entertainment Also in the news Video and Audio Have Your Say

Magazine In Pictures Country Profiles Special Reports 🕨 LIVE 💵 BBC NEWS CHANNEL

Last Updated: Wednesday, 1 February 2006, 07:02 GMT

E-mail this to a friend Hospitals admit insulin overdoses

Hospitals in Northern Ireland have said staff gave wrong dosages of insulin to patients 33 times in recent years.

Two patients received fatal overdoses at Belfast's City Hospital. On another two occasions, incorrect amounts



occasions, incorrect amounts Two patients received fatal overdoses were administered to patients. at Belfast City Hospital

The Royal Victoria Hospital had nine cases of incorrect doses and seven hospitals had one to four incidents.

All NI hospitals were asked to check records for insulin overdoses over 10 years. Most were unable to do so.

BBC NI's health correspondent Dot Kirby said that last year, an inquest was held into the death of an elderly woman in the City Hospital in Belfast.

RELATED BBC SITES SPORT WEATHER CBBC NEWSROUND "She died in 2001 because a junior doctor gave her too much insulin. After her death, the hospital said they immediately instigated a number of measures to ensure that 'such events would not happen again,'" she said.



Print Close Window

Primary Care | August 2006 It's All in the Syringe

The Case

A 33-year-old man with type 2 diabetes presented to his physician's office to discuss his diabetes management. The patient admitted not taking his medications or checking his blood sugars regularly. In the office, his blood sugar was 335 mg/dL, so the nurse practitioner (NP) ordered 6 units of regular insulin to administer.

After the medical assistant brought the insulin and syringe, the NP prepared the medication and injected the insulin. Immediately after the injection, the NP discovered that a tuberculin syringe was used instead of an insulin one. As a result of the error, the patient inadvertently received 60 units of insulin rather than 6 units. The patient was given orange juice, a sandwich, and his blood sugars were closely monitored for 4 hours with no significant events.



Rapid Response Report

NPSA/2008/RRR001

From reporting to learning

22 January 2008